Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107447
Abstract: BACKGROUND Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA, also known as dual bronchodilator) and inhaled corticosteroid/LABA (ICS/LABA) are the cornerstone of maintenance treatment for stable chronic obstructive pulmonary disease (COPD) patients. We aimed to comprehensively compare the… read more here.
Keywords: chronic obstructive; long acting; inhaled corticosteroid; bronchodilator ... See more keywords
In tobacco smokers with respiratory symptoms, a dual bronchodilator did not reduce symptoms at 12 wk
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0103
Abstract: SOURCE CITATION Han MK, Ye W, Wang D, et al. Bronchodilators in tobacco-exposed persons with symptoms and preserved lung function. N Engl J Med. 2022;387:1173-84. 36066078. read more here.
Keywords: tobacco smokers; smokers respiratory; tobacco; respiratory symptoms ... See more keywords